• Figure 1.
    Download figureOpen in new tabFigure 1. A triangle of association testing.

    The following association analyses were performed: [Study A] human SNPs vs plasma viral load (1 GWAS); [Study B] human SNPs vs variable HIV-1 amino acids (3007 GWAS); and [Study C] variable HIV-1 amino acids vs plasma viral load (1 proteome-wide association study).

    DOI: http://dx.doi.org/10.7554/eLife.01123.003

    Figure 2.
    Download figureOpen in new tabFigure 2. Results of the genome-wide association analyses.

    (A) Associations between human SNPs and HIV-1 plasma viral load. The dotted line shows the Bonferroni-corrected significance threshold (p-value < 7.25 × 10−9). (B) Associations between human SNPs and HIV-1 amino acid variants, with 3007 GWAS collapsed in a single Manhattan plot. The dotted line shows the Bonferroni-corrected significance threshold (p-value < 2.4 × 10−12). (C) Schematic representation of the HLA class I genes and of the SNPs associated with HIV-1 amino acid variants in the region. (D) Same association results as in panel B, projected on the HIV-1 proteome. Only the strongest association is shown for each amino acid. Significant associations are indicated by a blue dot. The gp120 part of the HIV-1 proteome was not tested. The colored bar below the plot area shows the positions of the optimally defined CD8+ T cell epitopes. An interactive version of this figure can be found at http://g2g.labtelenti.org (which is also available to download from Zenodo, http://dx.doi.org/10.5281/zenodo.7138).

    DOI: http://dx.doi.org/10.7554/eLife.01123.004

    Figure 3.
    Download figureOpen in new tabFigure 3. Association of HIV-1 amino acid variants with plasma viral load.

    (A) Changes in VL (slope coefficients from the univariate regression model and standard error, log10 copies/ml) for the 48 HIV-1 amino acids that are associated with host SNPs in the genome-to-genome analysis. (B) rs2395029, a marker of HLA-B*57:01 is associated with a 0.38 log10 copies/ml lower VL (black bar) in comparison to the population mean. Gray bars represent changes in VL for amino acid variants associated with rs2395029 (p<0.001). In case of multiallelic positions, the change in VL is shown for all minor amino acids combined vs the major amino acid (e.g., GAG147 not I).

    DOI: http://dx.doi.org/10.7554/eLife.01123.006

  • Table 1.

    Associations between HIV-1 amino acid variants and human polymorphisms

    DOI: http://dx.doi.org/10.7554/eLife.01123.005

    HIV geneHIV positionSNPCTL epitope (codons)Tagging HLA (D’/r2)SNP vs aa (p)SNP vs VL (p)aa vs VL (p)
    GAG12chr6:31285512B*49:01 (1.00/1.00)2.20E-136.70E-015.60E-01
    GAG26rs12524487B*15:01 (1.00/0.82)6.10E-192.10E-011.40E-01
    GAG28rs1655912RLRPGGKKK (20–28)A*03:01 (1.00/0.81)2.70E-555.60E-012.00E-02
    GAG79chr6:31267544LYNTVATL (78-85)C*14:02 (1.00/0.96)2.40E-123.50E-012.80E-01
    GAG147rs1055821C*06:02 (0.95/0.71)3.10E-173.30E-072.90E-05
    GAG242rs73392116TSTLQEQIGW (240–249)B*57:01 (1.00/0.98)2.40E-621.90E-061.70E-05
    GAG248rs41557213TSTLQEQIGW (240-249)B*57:01 (1.00/0.97)4.80E-152.00E-065.30E-03
    GAG264chr6:31376564KRWIILGLNK (263–272)B*27:05 (1.00/0.92)2.30E-135.50E-023.50E-01
    GAG268rs2249935GEIYKRWIIL (259–268)B*08:01 (1.00/0.43)2.20E-145.10E-011.90E-01
    GAG340rs11966319B*15:01 (0.94/0.42)6.70E-144.60E-017.70E-01
    C*03:04 (0.99/0.59)
    GAG357rs2523612GPGHKARVL (355-363)B*07:02 (0.99/0.95)2.70E-192.20E-011.20E-01
    C*07:02 (0.99/0.84)
    GAG397rs61754472A*31:01 (0.97/0.83)8.80E-213.50E-018.30E-01
    GAG403rs288965718.90E-217.90E-018.60E-01
    GAG437rs34268928RQANFLGKI (429-437)B*13:02 (1.00/0.96)8.70E-141.80E-026.80E-02
    GP41206rs17881210B*15:01 (1.00/0.88)6.10E-176.10E-013.00E-01
    GP41267rs9278477RLRDLLLIVTR (259–269)A*03:01 (1.00/0.01)1.00E-127.80E-012.60E-01
    INT11rs2596477B*44:02 (1.00/0.64)5.10E-331.50E-011.80E-01
    INT32rs1050502B*51:01 (0.97/0.92)4.80E-187.20E-014.00E-01
    INT119rs9264954C*05:01 (1.00/1.00)1.30E-247.90E-011.10E-01
    INT122rs9264419C*05:01 (1.00/0.95)4.50E-228.30E-017.80E-01
    INT124chr6:31345421STTVKAACWW (123–132)B*57:01 (1.00/1.00)3.00E-131.10E-069.70E-03
    NEF71rs2596488FPVTPQVPLR (68–77)B*07:02 (1.00/0.98)3.80E-552.50E-018.10E-02
    C*07:02 (0.95/0.83)
    NEF81rs9295987RPMTYKAAL (77–85)B*07:02 (1.00/0.01)4.80E-362.50E-019.50E-02
    C*04:01 (0.90/0.63)
    NEF83rs34768512B*15:01 (1.00/0.47)2.20E-172.80E-011.50E-02
    C*03:04 (0.96/0.54)
    NEF85rs2395475RPMTYKAAL (77–85)B*07:02 (1.00/0.29)1.90E-248.10E-011.30E-03
    B*08:01 (1.00/0.22)
    C*07:02 (0.97/0.30)
    NEF92rs16896166AVDLSHFLK (84–92)A*11:01 (1.00/0.99)1.00E-275.30E-011.50E-01
    NEF94rs9265972FLKEKGGL (90–97)B*08:01 (1.00/0.97)9.60E-359.80E-011.20E-01
    NEF102rs2524277B*44:03 (0.98/0.96)1.10E-134.40E-012.40E-01
    NEF105rs1049709C*07:01 (1.00/0.98)1.10E-359.00E-012.70E-01
    NEF116chr6:31402358HTQGYFPDW (116–124)B*57:01 (1.00/1.00)3.00E-221.90E-063.30E-01
    NEF120chr6:31236168-C*14:02 (1.00/1.00)4.40E-163.60E-011.20E-02
    NEF126chr6:31102273B*51:01 (1.00/0.18)1.10E-121.80E-014.90E-02
    NEF133chr6:31397689B*35:01 (0.95/0.89)2.80E-192.50E-013.40E-01
    NEF135rs72845950RYPLTFGW (134–141)A*24:02 (1.00/0.88)2.70E-669.10E-025.50E-03
    PR35rs2523577EEMNLPGRW (34-42)B*44:02 (1.00/0.64)1.70E-181.60E-015.70E-01
    PR93rs2263323B*15:01 (0.98/0.92)5.60E-304.70E-019.50E-01
    RNASE28rs2428481B*08:01 (1.00/1.00)1.80E-128.10E-016.20E-01
    RT135rs1050502TAFTIPSI (128–135)B*51:01 (0.97/0.92)6.70E-457.20E-013.00E-01
    RT245chr6:31411714IVLPEKDSW (244–252)B*57:01 (1.00/0.98)2.90E-211.20E-065.40E-02
    RT277rs3128902QIYPGIKVR (269–277)A*03:01 (1.00/0.99)1.20E-658.20E-012.70E-01
    RT369rs17190134B*13:02 (0.93/0.86)3.50E-206.40E-021.40E-01
    RT395rs17194293-1.50E-121.20E-017.70E-02
    TAT29rs9260615A*32:01 (0.98/0.95)4.40E-143.90E-011.40E-01
    TAT32rs16899214CCFHCQVC (30–37)C*12:03 (0.98/0.96)6.40E-213.40E-014.90E-01
    VIF33chr6:31430060ISKKAKGWF (31–39)B*57:01 (1.00/0.98)1.50E-139.90E-079.30E-03
    VIF51rs7767850B*49:01 (1.00/1.00)1.40E-125.20E-012.10E-01
    VIF74rs2395029B*57:01 (1.00/0.98)5.40E-139.70E-072.80E-01
    VPR32chr6:31362941VRHFPRIWL (31–39)B*27:05 (1.00/0.94)3.10E-135.40E-026.50E-01
    • Significant associations (p < 2.4 × 10-12) were observed for 48 HIV-1 amino acid variants. The table shows the major amino acid variants present at each specific HIV-1 position, the strongest associated SNP and its linked HLA class I allele(s), if applicable. The column ‘CTL Epitope (codons)’ lists published, optimally described CTL epitopes (available at http://www.hiv.lanl.gov/content/immunology/tables/optimal_ctl_summary.html and in [Carlson et al., 2012]) restricted by the tagged HLA class I allele(s) specified, and their positions within the protein. Where multiple overlapping epitopes restricted by the same HLA class I allele have been described, only one is shown. Associations where no relevant CTL epitope has been described are indicated with a dash. The last three columns give association p-values for comparisons between human SNPs and viral amino acids, human SNPs and plasma VL and viral amino acids and plasma VL, respectively. For tests involving viral amino acids accommodating more than 1 alternate allele, the smallest association p-value observed at that position is reported.

  • Table 2.

    Distribution of samples across genotyping platforms and cohorts

    DOI: http://dx.doi.org/10.7554/eLife.01123.007

    NGenotyping platformCohort
    140Illumina 1MACTG
    6Illumina OmniExpress 12v1HCARLOS III
    518Affymetrix 6.0HOMER
    136Illumina OmniExpress12v1HHOMER
    47Illumina 650kIHCS
    6Illumina 660W-QuadIRSICAIXA
    2Illumina 1MSHCS
    79Illumina 550kSHCS
    122Illumina OmniExpress12v1HSHCS
    15Illumina 550kWAHCS
    • ACTG = AIDS Clinical Trials Group Network; CARLOS III = Instituto de Salud Carlos III; HOMER = HAART Observational Medical Evaluation and Research Study; IHCS = International HIV Controllers Study; IRSICAIXA = AIDS Research Institute IrsiCaixa; SHCS = Swiss HIV Cohort Study; WAHCS = Western Australian HIV Cohort Study.